WBP1 Antibody

What is WBP1 and what is the function of WBP1 in cellular processes?

WBP1 (WW domain binding protein 1) is a 32 kDa type I transmembrane protein that was originally identified in vitro as a protein binding to the WW domain of Yes kinase-associated protein . Research has demonstrated that silencing of WBP1 using small hairpin RNAs (shRNAs) resulted in partial but significant suppression of ATF6-induced apoptosis, suggesting its potential role in cellular stress responses and programmed cell death pathways . The protein appears to have functional significance in apoptotic regulation, although complete characterization of all its cellular functions is still ongoing in current research.

What are the available types of WBP1 antibodies and their basic properties?

Based on the available research data, there are several types of WBP1 antibodies with distinct properties:

The antibodies are typically generated using either full WBP1 protein or specific segments as immunogens . These antibodies recognize the target WBP1 protein at approximately 32 kDa molecular weight in experimental applications .

How should WBP1 antibodies be stored and handled for optimal performance?

For optimal preservation of antibody activity, WBP1 antibodies should be stored at -20°C where they remain stable for one year after shipment . The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . According to manufacturer specifications, aliquoting is unnecessary for -20°C storage, which simplifies laboratory handling protocols . When working with smaller quantities, it's important to note that some preparations (20μl sizes) contain 0.1% BSA as a stabilizer . Proper storage and handling are critical for maintaining antibody specificity and sensitivity in experimental applications.

What are the recommended dilutions for different applications of WBP1 antibody?

The optimal dilution ranges for WBP1 antibodies vary by application type and specific antibody:

It is strongly recommended that researchers titrate these antibodies in each specific testing system to obtain optimal results, as performance can be sample-dependent . For Western blot applications, validation data shows successful detection at 1:3000 dilution with 25μg protein per lane, using 3% non-fat dry milk in TBST as blocking buffer and ECL detection with 90-second exposure .

What sample preparation methods are optimal for detecting WBP1 using antibody-based techniques?

For Western blot applications, cell or tissue lysates should be prepared to ensure optimal WBP1 detection. Based on validation data, protein concentrations of approximately 25μg per lane are sufficient for detection in various cell lines . For IHC applications with the 11042-1-AP antibody, antigen retrieval should be performed using TE buffer (pH 9.0), although citrate buffer (pH 6.0) can serve as an alternative .

When working with tissue samples, positive WBP1 detection has been validated in mouse brain tissue for Western blotting and human pancreatic cancer tissue for IHC applications . These tissue types can serve as positive controls for experimental validation. The methodology should be adapted based on the specific tissue or cell type being investigated, with particular attention to antigen retrieval methods for fixed tissues.

What are common causes of non-specific binding when using WBP1 antibodies and how can they be mitigated?

Non-specific binding can occur with WBP1 antibodies, particularly in Western blot applications. Validation data indicates that apparent bands below the expected 32 kDa WBP1 band may represent non-specific binding or degradation products . To minimize non-specific binding:

• Optimize blocking conditions: 3% non-fat dry milk in TBST has been validated for WBP1 antibody applications in Western blot .

• Adjust antibody dilution: Higher dilutions (e.g., 1:3000 for WB) may reduce background while maintaining specific signal .

• Include appropriate controls: Always include positive controls (e.g., mouse brain tissue for WB, human pancreatic cancer tissue for IHC) and negative controls to distinguish specific from non-specific signals .

• Optimize washing steps: Increasing wash duration or number of washes can help reduce background signal without compromising specific binding.

If smaller bands persist below the expected 32 kDa mark, these might represent degradation products of the N-terminal region of WBP1, a phenomenon observed with similar proteins in other studies .

How can researchers validate the specificity of WBP1 antibodies in their experimental systems?

To validate WBP1 antibody specificity, researchers should employ multiple complementary approaches:

• Molecular weight verification: Confirm detection of the expected 32 kDa band in Western blot applications .

• Positive and negative controls: Use known positive samples (mouse brain tissue for WB, human pancreatic cancer tissue for IHC) and appropriate negative controls .

• Knockdown/knockout verification: Although not detailed in the provided data, knockdown/knockout experimental approaches have been published for WBP1, suggesting this as a viable validation strategy .

• Cross-reactivity assessment: Test antibody performance across multiple species if multi-species reactivity is claimed (human, mouse, rat) to confirm consistent patterns of detection .

• Comparison with alternative antibody clones: When possible, compare results using different antibodies targeting distinct epitopes of WBP1 to confirm consistent detection patterns.

The comprehensive validation process ensures that experimental findings based on WBP1 antibody detection truly reflect the biology of the target protein rather than artifacts.

How can WBP1 antibodies be utilized to investigate protein-protein interactions involving WBP1?

WBP1 was originally identified through its interaction with the WW domain of Yes kinase-associated protein . To investigate such protein-protein interactions:

• Co-immunoprecipitation (Co-IP): WBP1 antibodies can be used to pull down WBP1 along with its interacting partners from cell lysates. While specific Co-IP protocols aren't provided in the search results, the antibodies would be suitable for this application given their specificity for WBP1.

• Proximity ligation assay (PLA): For detecting in situ protein interactions, WBP1 antibodies can be paired with antibodies against suspected interaction partners.

• Immunofluorescence co-localization: The A89120 antibody's validated use in ICC/IF applications (1:50-1:100 dilution) makes it suitable for co-localization studies with potential interaction partners .

• Pull-down assays with recombinant proteins: To validate direct interactions, recombinant WBP1 can be used alongside WBP1 antibodies for detection in pull-down experiments.

These approaches can help elucidate WBP1's role in cellular signaling networks, particularly in relation to the Yes kinase pathway and ATF6-mediated apoptosis regulation .

What is the role of WBP1 in apoptosis regulation and how can WBP1 antibodies help elucidate this mechanism?

Research has shown that silencing WBP1 with small hairpin RNAs causes partial but significant suppression of ATF6-induced apoptosis . To further investigate this mechanism:

• Protein expression correlation: WBP1 antibodies can be used to monitor WBP1 expression levels in various apoptotic conditions via Western blot, correlating its expression with apoptotic markers.

• Subcellular localization during apoptosis: Using the A89120 antibody for ICC/IF (1:50-1:100 dilution), researchers can track WBP1 translocation during apoptotic stimulus .

• Protein modifications during apoptosis: Western blot analysis with WBP1 antibodies can detect potential post-translational modifications that might occur during apoptotic signaling.

• Integration with ATF6 pathway analysis: Combined detection of WBP1 and ATF6 pathway components can help map the regulatory relationship between these factors in apoptotic regulation.

Understanding WBP1's role in apoptosis has significant implications for cancer research and cellular stress response mechanisms, making this a valuable area for further investigation using WBP1-specific antibodies.

How should researchers approach epitope mapping for WBP1 antibodies?

Epitope mapping is crucial for understanding antibody specificity and functionality. For WBP1 antibodies:

• Recombinant fragment analysis: The A89120 antibody targets amino acids 170-269 of human WBP1 , while the immunogen for 11042-1-AP is the WBP1 fusion protein Ag1478 . Researchers can create overlapping peptide fragments spanning these regions to precisely map the epitope.

• Alanine scanning mutagenesis: Following the methodology demonstrated in epitope mapping of broad-spectrum antibodies , alanine substitution of individual amino acids can identify critical residues for antibody binding.

• Cross-species reactivity analysis: Comparing the conservation of epitope regions across species (human, mouse, rat) can provide insights into essential binding determinants, as both antibodies show cross-species reactivity .

• Competitive binding assays: Using synthetic peptides corresponding to potential epitope regions to compete with antibody binding to the full protein.

Epitope mapping provides valuable information for antibody characterization and can inform experimental design, particularly when multiple antibodies are used in combination or when epitope masking is a concern.

What considerations are important when using WBP1 antibodies in multiplex immunofluorescence applications?

For multiplex immunofluorescence experiments involving WBP1 antibodies:

• Antibody compatibility: When using the A89120 rabbit polyclonal antibody, pair it with antibodies raised in different host species (e.g., mouse, goat) to avoid cross-reactivity of secondary antibodies .

• Optimization of dilution: For ICC/IF applications, the recommended 1:50-1:100 dilution of A89120 should be carefully titrated in multiplex settings to balance signal strength across all targets .

• Sequential staining considerations: For challenging multiplex panels, consider sequential staining protocols that may include antibody stripping or inactivation between rounds.

• Spectral overlap: Choose fluorophores with minimal spectral overlap when designing secondary antibody combinations, and include appropriate controls to assess and correct for any bleed-through.

• Validation of staining patterns: Confirm that the staining pattern of WBP1 in multiplex panels matches that observed in single-antibody staining experiments to ensure specificity is maintained.

These considerations help ensure reliable and interpretable results when incorporating WBP1 detection into complex multiplex immunofluorescence protocols.

How should researchers interpret variations in WBP1 band patterns in Western blot experiments?

When analyzing Western blot results with WBP1 antibodies, researchers may observe variable banding patterns that require careful interpretation:

• Expected molecular weight: The primary WBP1 band should appear at approximately 32 kDa, which corresponds to both the calculated and observed molecular weight of WBP1 .

• Lower molecular weight bands: Bands appearing below the expected 32 kDa may represent:

  • Degradation products, particularly from the N-terminus

  • Non-specific binding, which can be reduced through optimization of blocking and washing protocols

  • Potential isoforms or post-translationally modified variants of WBP1

• Sample-dependent variations: Different cell lines may show slight variations in band intensity or minor size shifts due to post-translational modifications specific to certain cellular contexts .

• Loading controls: Normalization to appropriate loading controls is essential for quantitative comparisons of WBP1 expression across different samples or conditions.

Validation data shows that when using the A89120 antibody at 1:3000 dilution with 25μg protein per lane, clear specific bands can be detected with a 90-second exposure using ECL detection .

What are the best practices for quantitative analysis of WBP1 expression using antibody-based techniques?

For reliable quantitative analysis of WBP1 expression:

Following these practices ensures that quantitative comparisons of WBP1 expression are reliable and reproducible across experiments.

How can WBP1 antibodies be utilized in exploring the relationship between WBP1 and cellular stress responses?

Given WBP1's role in ATF6-induced apoptosis , WBP1 antibodies can facilitate research into cellular stress responses through:

• Stress pathway activation studies: Monitor WBP1 expression and localization changes during various cellular stressors (oxidative stress, ER stress, hypoxia) using Western blot (1:500-1:3000 dilution) and ICC/IF (1:50-1:100 dilution) .

• Temporal dynamics analysis: Track WBP1 expression changes over time following stress induction to determine the kinetics of its involvement in stress response pathways.

• Co-localization with stress response factors: Use the A89120 antibody in ICC/IF applications to investigate potential co-localization or interaction with stress-related proteins like ATF6, PERK, or IRE1 .

• Tissue-specific stress responses: Apply the 11042-1-AP antibody in IHC (1:50-1:500 dilution) to examine WBP1 expression in tissues under pathological stress conditions, such as ischemia or inflammation .

These approaches can help elucidate WBP1's functional role in cellular adaptation to stress, potentially revealing new therapeutic targets for stress-related pathologies.

What methodological advances might enhance the utility of WBP1 antibodies in single-cell protein analysis?

Emerging methodological advances for single-cell protein analysis with WBP1 antibodies include:

• Mass cytometry (CyTOF): Metal-conjugated WBP1 antibodies could enable high-dimensional analysis of WBP1 expression alongside numerous other proteins at the single-cell level, avoiding fluorescence spectrum limitations.

• Single-cell Western blotting: Adapting WBP1 antibodies (11042-1-AP, A89120) to microfluidic single-cell Western blot platforms using validated dilutions (1:500-1:3000) .

• In situ sequencing with antibody detection: Combining WBP1 antibody staining with in situ RNA sequencing to correlate protein expression with transcriptional profiles at the single-cell level.

• Microfluidic antibody capture: Using WBP1 antibodies in microfluidic devices to capture and quantify protein from individual cells.

• Super-resolution microscopy: Applying the ICC/IF-validated A89120 antibody (1:50-1:100 dilution) with super-resolution techniques to visualize the nanoscale distribution of WBP1 within individual cells .

These advanced methodologies can provide unprecedented insights into cell-to-cell variation in WBP1 expression and its relationship to cellular function and disease states.